99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer|Female
Interventions: DRUG: 99mTc-DARPinG3
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborators: Uppsala University